Liquidia's stock fell sharply by 18.1% as investors reacted negatively to cautious guidance and anticipated margin pressure amid accelerating R&D and SG&A spending. Despite strong sales growth in YUTREPIA, concerns about escalating expenses and a slower-than-expected profitability trajectory weighed on sentiment.
- YUTREPIA net product sales reached $170.4 million in Q2 2026, up 31% sequentially, continuing a strong growth trajectory since launch.
- Net income rose to approximately $74.7 million and adjusted EBITDA to $96.3 million, reflecting improving operating leverage.
- Cash balance increased to $284.2 million, up $61.4 million from Q1 due to strong cash flow generation.
- R&D and SG&A expenses both increased this quarter driven by pipeline investments and expansion of the commercial sales team, with R&D expected to double in H2 2026 and rise further in 2027.
- Management emphasized ongoing and planned clinical trials (10 studies over next 12 months), indicating a clear ramp in development spending that could pressure margins going forward.
Community Discussion